Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $16.56.

Several equities analysts have commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Roivant Sciences from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Tuesday, November 14th. Guggenheim decreased their price target on shares of Roivant Sciences from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, November 15th. Piper Sandler started coverage on shares of Roivant Sciences in a research note on Friday, January 5th. They issued an “overweight” rating and a $20.00 price target on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Roivant Sciences in a research note on Tuesday, December 12th. They issued a “buy” rating and a $14.00 price target on the stock. Finally, Bank of America upped their price target on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Tuesday, January 2nd.

View Our Latest Analysis on Roivant Sciences

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $10.87 on Tuesday. The company’s fifty day simple moving average is $10.64 and its 200-day simple moving average is $10.49. The company has a quick ratio of 5.84, a current ratio of 5.84 and a debt-to-equity ratio of 0.29. The firm has a market cap of $8.74 billion, a PE ratio of -8.23 and a beta of 1.34. Roivant Sciences has a 12 month low of $6.59 and a 12 month high of $13.24.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.02. Roivant Sciences had a negative net margin of 951.77% and a negative return on equity of 73.04%. The firm had revenue of $37.10 million for the quarter, compared to analyst estimates of $26.68 million. Equities research analysts expect that Roivant Sciences will post -1.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the sale, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Eric Venker sold 96,950 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now owns 532,207 shares of the company’s stock, valued at $5,811,700.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 3,000,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $11.05, for a total transaction of $33,150,000.00. Following the completion of the transaction, the insider now directly owns 51,929,426 shares of the company’s stock, valued at approximately $573,820,157.30. The disclosure for this sale can be found here. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Citigroup Inc. raised its holdings in Roivant Sciences by 1,803.6% in the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after buying an additional 5,447 shares during the last quarter. Royal Bank of Canada raised its holdings in Roivant Sciences by 60,550.0% in the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock valued at $30,000 after buying an additional 6,055 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Roivant Sciences in the 4th quarter valued at approximately $33,000. Headlands Technologies LLC bought a new position in Roivant Sciences in the 4th quarter valued at approximately $36,000. Finally, Allspring Global Investments Holdings LLC bought a new position in Roivant Sciences in the 3rd quarter valued at approximately $44,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

(Get Free Report

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.